Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer

IntroductionThis study aimed to elucidate the relationship between dynamic genomic mutation alteration and pseudoprogression (PsPD)/hyperprogressive disease (HPD) in immunotherapy-treated advanced non-small-cell lung cancer (NSCLC), to provide clinical evidence for identifying and distinguishing bet...

Full description

Bibliographic Details
Main Authors:	Rui Zhou, Fan Tong, Yongchang Zhang, Ruigang Zhang, Yawen Bin, Sheng Zhang, Nong Yang, Xiaorong Dong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Oncology
Subjects:	next-generation sequencing analysis pseudoprogression hyperprogressive disease anti-PD1 treatment non-small cell lung cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1231094/full

Similar Items

Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01)

Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition
by: Yikun Li, et al.
Published: (2024-12-01)

Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
by: Huijie Zhou, et al.
Published: (2023-03-01)

Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence
by: Jianpei Zheng, et al.
Published: (2023-02-01)

Pseudoprogression in patients on immunotherapy
by: D. I. Yudin, et al.
Published: (2019-06-01)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
by: Yanping Li, et al.
Published: (2023-05-01)

IFN-γ and CD38 in Hyperprogressive Cancer Development
by: Stefania Angelicola, et al.
Published: (2021-01-01)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
by: Shiyun Chen, et al.
Published: (2023-08-01)

Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
by: Mikolaj Kocikowski, et al.
Published: (2020-03-01)

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Wang X, et al.
Published: (2023-01-01)

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
by: Jong Yeob Kim, et al.
Published: (2019-11-01)

Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
by: Hasan Cagri Yildirim, et al.
Published: (2022-09-01)

Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature
by: Jan Skacel, et al.
Published: (2023-12-01)

Pseudoprogression; discussion of the concept of pseudoprogression on the characteristics of tomographic changes in liver metastases of colorectal cancer patients receiving bevacizumab therapy
by: Pinar Ozdemir Akdur, et al.
Published: (2023-09-01)

Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review
by: Jiajie He, et al.
Published: (2023-11-01)

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
by: Hugo Arasanz, et al.
Published: (2020-02-01)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
by: Zhanqi Wei, et al.
Published: (2022-05-01)

The Potential Use of Radiomics with Pre-Radiation Therapy MR Imaging in Predicting Risk of Pseudoprogression in Glioblastoma Patients
by: Michael Baine, et al.
Published: (2021-01-01)

Hyperprogressive Disease: Main Features and Key Controversies
by: Hugo Arasanz, et al.
Published: (2021-04-01)

Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
by: Zhu W, et al.
Published: (2023-09-01)

The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence
by: Kashif Parvez, et al.
Published: (2014-07-01)

Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report
by: Changshun Wu, et al.
Published: (2022-12-01)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
by: Nozomi Hayakawa, et al.
Published: (2023-01-01)

The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles
by: Serena Indino, et al.
Published: (2022-12-01)

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
by: Amrit S. Gonugunta, et al.
Published: (2022-07-01)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Andrea Alberti, et al.
Published: (2022-06-01)

Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review
by: Ingrid Sidibe, et al.
Published: (2022-01-01)

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
by: Yongbo Xiang, et al.
Published: (2023-07-01)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
by: Takumi Kageyama, et al.
Published: (2022-11-01)

Machine Learning Model to Predict Pseudoprogression Versus Progression in Glioblastoma Using MRI: A Multi-Institutional Study (KROG 18-07)
by: Bum-Sup Jang, et al.
Published: (2020-09-01)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
by: H. S. Gabryś, et al.
Published: (2022-11-01)

Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
by: Kosuke Masuda, et al.
Published: (2023-11-01)

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
by: Sae Yumita, et al.
Published: (2023-03-01)

Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?
by: Alkader Mohammad S., et al.
Published: (2024-03-01)

Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
by: Amy Junghyun Lee, et al.
Published: (2021-05-01)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
by: Eun Young Kim, et al.
Published: (2019-04-01)

Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report
by: Keita Ogasawara, et al.
Published: (2022-11-01)

Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
by: Yaping Long, et al.
Published: (2023-09-01)

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
by: Yusuke Kunimatsu, et al.
Published: (2023-04-01)

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report
by: Aijuan Tian, et al.
Published: (2023-01-01)